✨ Free AI Report
OraSure Technologies, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research OraSure Technologies, Inc.
Company Research

OraSure Technologies, Inc.: Business Overview, Financials & Competitive Analysis

OraSure Technologies is a diagnostic and medical device company specializing in point-of-care and self-testing products, with a portfolio of oral fluid and non-invasive specimen collection technologies that support de...

Analyst-debate audio for OraSure Technologies, Inc.

AskCyborg analysts argue the bull and bear cases for OraSure Technologies, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
4/ 10Weak

Cyborg Score thesis

Turnaround story with near-term product catalysts but facing significant execution risk amid challenging market conditions and...

Read the full analyst-debate transcript →
Industry In Vitro Diagnostics (IVD) / Medical Devices - Point-of-Care and Specimen Collection
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest OraSure Technologies, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

OraSure Technologies, Inc. Overview

Pro stress-test →

OraSure Technologies is a diagnostic and medical device company specializing in point-of-care and self-testing products, with a portfolio of oral fluid and non-invasive specimen collection technologies that support detection of infectious diseases, drugs of abuse, and health biomarkers. The company's flagship product, the OraQuick® rapid HIV test, was the first FDA-approved over-the-counter oral fluid test for HIV detection.

Strategic Profile

Pro stress-test →

The company reported Q4 2025 revenue of $26.8 million with management pointing to early signs of stabilization across key end markets after a transition year marked by a challenging funding environment. Executives highlighted two mid-year 2026 product launches as near-term growth catalysts, following FDA submissions made in December. Entering 2026, the company is seeing "increasing signs of stability in key segments," including improved visibility to funding for testing and research programs.

Competitive Landscape

Pro stress-test →

QuidelOrtho is identified as one of OraSure's 46 competitors. The company competes in the broader in vitro diagnostic testing market with point-of-care and self-testing products. OraSure's competitive advantages include its non-invasive specimen collection technologies, flagship OraQuick brand recognition, and expanding sample management solutions for genomic and precision medicine applications.

Industry Context

OraSure Technologies, Inc. operates in In Vitro Diagnostics (IVD) / Medical Devices - Point-of-Care and Specimen Collection.

Key facts

Founded: 2000 · Headquarters: Bethlehem, Pennsylvania · Revenue: $115.0M (2025 full year) · Market cap: $194M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on OraSure Technologies, Inc..

  • Two FDA applications submitted in December for rapid molecular OTC self-test for chlamydia/gonorrhea (Sherlock) and Colli-Pee at-home urine collection device, targeting mid-year launches with CT/NG TAM of >$1.5 billion.
  • International diagnostics trends are stabilizing with nearshoring (in-country assembly in Africa) expected to contribute revenue in Q1 and throughout 2026.
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Health Canada licensing approval for OraQuick HIV Self-Test for use in Canada
  • February 2026Q4 2025 results reported with signs of market stabilization and midyear product launch catalysts
  • +2 moreTrack every material event for OraSure Technologies, Inc. as it happens. Explore monitoring →
Get alerted when OraSure Technologies, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Rapid Diagnostic Tests & Sample CollectionPoint-of-care diagnostics competitor→Molecular DiagnosticsInfectious disease and molecular testing solutions→STI Rapid TestsSTI and infectious disease testing platforms→

Compare OraSure Technologies, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

OraSure Technologies, Inc. operates in In Vitro Diagnostics (IVD) / Medical Devices - Point-of-Care and Specimen Collection. See how the rest of the sector scores on the Cyborg framework.

Browse In Vitro Diagnostics (IVD) / Medical Devices - Point-of-Care and Specimen Collection research →
NEW · MCP server

Ask your AI assistant about OraSure Technologies, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare OraSure Technologies, Inc. and its top competitor on Cyborg Score”
“What did OraSure Technologies, Inc. do this quarter?”
“Is OraSure Technologies, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does OraSure Technologies, Inc. do?+
OraSure Technologies is a diagnostic and medical device company specializing in point-of-care and self-testing products, with a portfolio of oral fluid and non-invasive specimen collection technologies that support de...
What is OraSure Technologies, Inc.'s Cyborg Score?+
OraSure Technologies, Inc. has a Cyborg Score of 4/10 (Weak). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are OraSure Technologies, Inc.'s main competitors?+
Named competitors include Rapid Diagnostic Tests & Sample Collection, Molecular Diagnostics, STI Rapid Tests. The full competitive landscape is in the AskCyborg report.
How can I get the full OraSure Technologies, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the OraSure Technologies, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track OraSure Technologies, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More In Vitro Diagnostics (IVD) research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7bioMérieux S.A.7Eurobio Scientific7Gentian Diagnostics ASA5BioPorto A/S5EKF Diagnostics Holdings plc